EVP, Scientific Strategy & CSO of Exelixis Inc (30-Year Financial, Insider Trades) Peter Lamb (insider trades) sold 50,000 shares of EXEL on 04/06/2020 at an average price of $17.26 a share. The total sale was $863,000.
Exelixis Inc is a biotechnology company. It is involved in discovery, development, and commercialization of new medicines for people with cancer. The Cabometyx product generates maximum revenue for the company. Exelixis Inc has a market cap of $5.69 billion; its shares were traded at around $18.63 with a P/E ratio of 18.26 and P/S ratio of 6.05. GuruFocus has detected 1 severe warning sign with Exelixis Inc. .
Directors and Officers Recent Trades:
- EVP, Scientific Strategy & CSO Peter Lamb sold 50,000 shares of EXEL stock on 04/06/2020 at the average price of $17.26. The price of the stock has increased by 7.94% since.
- Director Jack L Wyszomierski sold 13,848 shares of EXEL stock on 04/03/2020 at the average price of $16.57. The price of the stock has increased by 12.43% since.
- Director George A Scangos sold 1,500 shares of EXEL stock on 03/31/2020 at the average price of $18.06. The price of the stock has increased by 3.16% since.
- EVP, Commercial Patrick J. Haley sold 4,318 shares of EXEL stock on 03/20/2020 at the average price of $15.37. The price of the stock has increased by 21.21% since.
For the complete insider trading history of EXEL, click here
.
